%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%  "NATURE-LENGTH" EXTREME EXAMPLE PAPER IN IEEE STYLE (Approximated ~20 pages)
%  The user requested a ~5x expansion of content, adding deep reasoning steps
%  and multiple data tables for a more thorough "Nature-like" scientific style.
%  By: ChatGPT
%  Last updated: 2025-01-20
%
%  NOTE:
%  1) This code is intentionally verbose to produce many pages in 2-column format.
%  2) If images are missing, you can comment out or replace the lines with
%     \includegraphics to prevent "file not found" compilation errors.
%  3) Compile with XeLaTeX + Biber steps to properly handle references.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\documentclass[journal]{IEEEtran}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% PACKAGES
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage[T1]{fontenc}
\usepackage{xcolor}      % Allows color
\usepackage{graphicx}    % For figures
\usepackage{float}       % For "H" specifier in figure
\usepackage{amsmath}     % For math
\usepackage{amssymb}
\usepackage{booktabs}    % For fancy tables
\usepackage{url}         % For \url command
\usepackage[style=ieee,backend=biber]{biblatex}
\usepackage{hyperref}    % Hyperlinks
\usepackage{lipsum}      % Sample text
\usepackage{siunitx}     % For SI units
\usepackage{enumitem}    % For custom itemize/enumerate

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% BIBLIOGRAPHY
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\addbibresource{\jobname.bib} 
% This means we embed a .bib file at the bottom of this .tex file 
% called the same name as the .tex file.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% CUSTOM COMMANDS
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\newcommand{\figref}[1]{Fig.~\ref{#1}}
\newcommand{\tabref}[1]{Table~\ref{#1}}
\newcommand{\secref}[1]{Section~\ref{#1}}
\newcommand{\appref}[1]{Appendix~\ref{#1}}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% BEGIN DOCUMENT
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\begin{document}

\title{Epigenetic Profiling of ME/CFS and Long COVID:\\
A Transformer-Based Approach to \\ \vspace{0.25em} 
Biomarker Discovery and Differentiation\vspace{-0.5em}}

\author{
  \IEEEauthorblockN{Piyush Acharya$^{1}$, Derek Jacoby$^{2}$, and the Epigenetics Research Group}%
  \thanks{Manuscript submitted January 2025.
  
  $^{1}$Department of Computational Biology, Example University, Bellevue, Washington, USA

  $^{2}$Department of Systems Medicine, Another University, Seattle, Washington, USA

  Corresponding author: Piyush Acharya (example@university.edu).
  }
}

\markboth{Preprint: Extended "Nature-Length" Example in IEEE Format, 2025}%
{Acharya \MakeLowercase{\textit{et al.}}: Epigenetic Profiling of ME/CFS and Long COVID}

\maketitle

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\begin{abstract}\vspace{-.3em}
\textit{%
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID, a post-acute sequela of SARS-CoV-2 infection, are both enigmatic conditions presenting persistent fatigue, immune dysregulation, and possibly epigenetic disturbances. In this extensive, 5x expanded paper, we detail a multi-stage experimental pipeline merging Illumina-based DNA methylation data with a Transformer-based model for biomarker discovery and disease differentiation. We adopt thorough data preprocessing (noob, functional normalization, cross-reactive probe filtering) and then use an autoencoder to compress the high-dimensional methylation features. We subsequently train a multi-head self-attention classifier (Transformer) to distinguish ME/CFS, Long COVID, and healthy controls. Over roughly 20 pages, we delve into rationales, literature expansions, and data tables illustrating differential methylation. We highlight both shared immuno-epigenetic traits and distinct metabolic gene perturbations across diseases. This integrated approach underscores the significance of modern deep learning in exploring chronic post-viral syndromes and sets a foundation for personalized therapeutic avenues.
}\vspace{-.6em}
\end{abstract}

\begin{IEEEkeywords}
ME/CFS, Long COVID, DNA Methylation, Transformer, Autoencoder, Epigenetics, Machine Learning, Chronic Fatigue
\end{IEEEkeywords}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\section{Introduction}\label{sec:intro}
\IEEEPARstart{M}{yalgic} encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disorder that has perplexed clinicians and researchers for decades \cite{Apostolou2024reprogramming}. Characterized by profound and unrelenting fatigue, it is accompanied by post-exertional malaise (PEM), neurocognitive dysfunction, and sometimes dysautonomia. Although first described in the 1980s under various monikers (including chronic fatigue immune deficiency syndrome), ME/CFS continues to challenge diagnostic clarity and precise biomarker identification.

\vspace{0.5em}
\noindent\textbf{Reasoning Step 1: The Emergence of Long COVID as a Parallel Condition.} 
A new condition, Long COVID or post-acute sequelae of SARS-CoV-2 (PASC), emerged during the COVID-19 pandemic \cite{Davis2023longCOVID}. Like ME/CFS, Long COVID patients often suffer from prolonged fatigue, cognitive “brain fog,” and persistent immunological irregularities well after clearance of the acute viral infection. This striking overlap in clinical presentation has led many researchers to question whether Long COVID might share fundamental pathophysiological mechanisms with ME/CFS \cite{Balnis2022persistent}. Could epigenetic processes be anchoring these chronic, post-viral states?

\vspace{0.5em}
\noindent\textbf{Reasoning Step 2: Epigenetics as the Bridge Between Viral Exposure and Chronic Symptoms.} 
Epigenetics, particularly DNA methylation (DNAm), is an attractive mechanism to explain how viral exposures can trigger a lingering, stable shift in gene expression \cite{Bejaoui2023epigeneticAge}. Epigenetic alterations can persist even after viral clearance, potentially driving prolonged immune dysfunction and metabolic reprogramming. In parallel, advanced high-throughput DNAm arrays—like the Illumina 450K and EPIC platforms—offer a broad snapshot of these modifications, thus enabling epigenome-wide association studies (EWAS). By comparing ME/CFS, Long COVID, and healthy controls, we can identify patterns of differential methylation that are either shared or distinct across conditions.

\vspace{0.5em}
\noindent\textbf{Reasoning Step 3: Complexity of Methylation Data Requires Robust Tools.} 
While classical EWAS approaches use univariate statistics (e.g., \texttt{limma}) to detect differentially methylated positions, they often fail to exploit intricate, higher-order relationships in the data \cite{Raushert2020machine}. With $\sim$700K probes in EPIC arrays, conventional methods can be statistically underpowered or overshadowed by noise. Hence, deep learning approaches—such as Transformers—are uniquely positioned to glean subtle patterns from large, high-dimensional input. Still, direct application is challenging due to the sheer data volume.

\vspace{0.5em}
\noindent\textbf{Reasoning Step 4: Our Autoencoder + Transformer Pipeline.} 
To manage high dimensionality, we implement an autoencoder that compresses DNAm features to a latent embedding (128D), capturing major variance. We then feed these embeddings into a Transformer-based classifier with multi-head self-attention. This synergy ensures robust dimensionality reduction, combined with the Transformer's capacity to identify global interactions among CpG sites, culminating in an effective classification scheme for (1) ME/CFS vs. controls, (2) Long COVID vs. controls, and (3) ME/CFS vs. Long COVID.

\vspace{0.5em}
\noindent\textbf{Reasoning Step 5: Objectives of this Study.} 
This work aims to:
\begin{enumerate}
\item Thoroughly compare DNAm signatures in ME/CFS and Long COVID to identify convergent or divergent pathways.
\item Evaluate the performance of an autoencoder+Transformer approach versus standard methods in discriminating these conditions.
\item Provide insight into epigenetic targets that could guide future diagnostic or therapeutic interventions.

\vspace{0.5em}
\item Clarify whether distinct epigenetic marks can illuminate separate disease subtypes, particularly within the broad realm of post-viral syndromes, thus refining personalized medicine approaches.
\end{enumerate}

\vspace{0.5em}
\noindent\textbf{Reasoning Step 6: Paper Outline.} 
The paper proceeds with an extended background on ME/CFS, Long COVID, and relevant epigenetic studies (\secref{sec:background}). \secref{sec:methods} details sample selection, data preprocessing, model architecture, and statistical analyses. \secref{sec:results} summarizes key findings, including autoencoder performance, classifier metrics, and top differentially methylated regions. A rich discussion (\secref{sec:discussion}) interprets these results with respect to host-virus interactions and clinical significance. Finally, we close with a thorough conclusion section highlighting future directions and the implications for improved biomarker discovery.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\section{Expanded Background}\label{sec:background}
This section provides an in-depth exposition on the current understanding of ME/CFS and Long COVID, focusing on the immunological and metabolic aberrations known to exist, and contextualizing the motivation for advanced epigenetic analyses.

\subsection{ME/CFS Pathophysiology}
\textbf{Reasoning Step 1: Clinical Complexity.}
ME/CFS is a notoriously heterogeneous disorder \cite{Apostolou2024reprogramming}. Patients experience a wide array of symptoms including musculoskeletal pain, orthostatic intolerance, and unrefreshing sleep. The hallmark, however, remains PEM—a delayed exacerbation of symptoms following even minor physical or mental exertion. Traditional laboratory tests often yield normal or inconclusive results, intensifying diagnostic challenges.

\textbf{Reasoning Step 2: Immunological Dysregulation.}
Studies have repeatedly shown elevated pro-inflammatory cytokines (e.g., IL-6, IL-1$\beta$), disrupted T-cell function, and reduced NK cell activity in ME/CFS patients \cite{Helliwell2020changesDNA}. Although not universal, these findings suggest a state of low-grade chronic inflammation. Researchers hypothesize an epigenetically mediated switch, possibly triggered by an initial viral infection, that perpetuates immune exhaustion or autoimmune-like features.

\textbf{Reasoning Step 3: Metabolic and Mitochondrial Abnormalities.}
Recent metabolomic investigations highlight defects in energy production pathways, with notable shifts in glycolysis and the TCA cycle. Some have reported diminished mitochondrial function, possibly reflecting an inability to meet increased energy demands \cite{Raushert2020machine}. DNAm changes near mitochondrial genes (e.g., \textit{NDUFS2}, \textit{COX8}) could partially explain the mismatch between energy demand and supply.

\textbf{Reasoning Step 4: Epigenetic Clues in ME/CFS.}
Epigenome-wide association studies have identified differentially methylated loci in \textit{NR3C1} (glucocorticoid receptor) and \textit{TRPM3} (ion channel) that correlate with symptom severity \cite{Helliwell2020changesDNA}. Furthermore, certain patterns of histone modifications have been observed, though less systematically studied. The notion that persistent DNAm changes could maintain a “locked-in” state of dysregulation is particularly appealing for explaining chronic, relapsing illnesses like ME/CFS.

\subsection{Long COVID Pathophysiology}
\textbf{Reasoning Step 1: Emergence from SARS-CoV-2.}
Long COVID first gained recognition when significant numbers of individuals failed to recover fully from acute COVID-19. Symptoms range from persistent respiratory complications to neurological deficits, but persistent fatigue and cognitive issues loom large \cite{Davis2023longCOVID}.

\textbf{Reasoning Step 2: Vascular and Endothelial Involvement.}
Compared to ME/CFS, Long COVID might feature an added layer of microvascular damage and clotting anomalies \cite{Balnis2022persistent}. SARS-CoV-2 is known to bind ACE2, found in endothelium, potentially triggering epigenetic reprogramming of endothelial cells. This can hamper blood flow regulation and oxygen delivery, compounding fatigue.

\textbf{Reasoning Step 3: Immune Residues from Acute Infection.}
SARS-CoV-2 triggers a robust immune response, including interferon pathways. Chronic upregulation or incomplete resolution of this response might be sustained via epigenetic marks around antiviral genes (e.g., \textit{IFI44L}, \textit{OAS1}). The presence of persistent viral RNA or proteins in certain tissues can also maintain an aberrant immune environment. Studies have shown that these epigenetic patterns do not revert to baseline even after clinical recovery \cite{Bejaoui2023epigeneticAge}.

\subsection{Shared Mechanistic Considerations}
\textbf{Reasoning Step 1: Overlapping Immune Activation.}
Both ME/CFS and Long COVID reflect states of immune hyperactivation or exhaustion. Common cytokine profiles, T-cell phenotypes, and NK cell dysfunction are seen in the literature \cite{Balnis2022persistent,Helliwell2020changesDNA}. This overlap suggests that immune epigenetic changes might be a unifying thread bridging the two conditions.

\textbf{Reasoning Step 2: Dysautonomia and Cardiovascular Symptoms.}
Orthostatic intolerance, POTS (postural orthostatic tachycardia syndrome), and microcirculatory issues appear in both conditions. Shared epigenetic modification in genes regulating vascular tone or autonomic nervous system function could explain these clinical parallels \cite{Liu2016evaluation}.

\textbf{Reasoning Step 3: Viral Trigger vs. Chronic Condition.}
Whereas ME/CFS triggers are often assumed to be older, more common viruses (EBV, HHV-6, etc.), Long COVID arises from SARS-CoV-2, a relatively novel pathogen. Distinctions in viral pathology might lead to partially overlapping but distinct methylation profiles.

\subsection{Why Transformers?}
\textbf{Reasoning Step 1: High-Dimensional Data.}
Each sample has hundreds of thousands of CpG loci, each potentially relevant for classification. Traditional machine learning struggles with the “curse of dimensionality” unless strong feature selection is used.

\textbf{Reasoning Step 2: Self-Attention Mechanisms.}
Transformers allow each position in a sequence (CpG site, in a rough analogy to “word” tokens in NLP) to attend to every other position, learning relationships that might unify or discriminate classes \cite{Raushert2020machine}.

\textbf{Reasoning Step 3: Coupling with Autoencoders.}
An autoencoder can reduce the dimensionality significantly (from 700K to 128), preserving essential variance while discarding noise. This compressed representation is then well-suited for a Transformer, which can interpret the 128D “sequence” effectively.

\subsection{Key Knowledge Gaps}
\textbf{Gap 1: Large-Scale Direct Comparison of ME/CFS vs. Long COVID.}
While there are multiple studies on ME/CFS epigenetics and emerging work on Long COVID, a direct epigenetic comparison remains sparse. Distinguishing how these conditions converge or diverge epigenetically is crucial for clarifying disease taxonomy.

\textbf{Gap 2: Advanced ML Implementation.}
Though random forests or SVMs have been used in smaller epigenetic subsets, fewer investigations leverage deep learning. Understanding the capacity of Transformers to handle these multi-class distinctions is a novel step.

\textbf{Gap 3: Biological Interpretation.}
Even if we find top-performing classifiers, mechanistic interpretation of discovered loci—particularly local or global patterns of immune/metabolic regulation—remains a significant challenge.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\section{Methods: In-Depth}\label{sec:methods}
We now detail how we collected data, processed methylation arrays, constructed the autoencoder+Transformer pipeline, and performed statistical analyses. 

\subsection{Participant Recruitment and Ethics}
\textbf{Reasoning Step 1: Recruitment Protocol.}
Participants for the ME/CFS cohort were recruited through specialized clinics using the Canadian Consensus Criteria to ensure a more stringent selection. Inclusion demanded a minimum 6-month history of classic ME/CFS symptoms with a mandatory presence of PEM. The Long COVID group encompassed individuals who had documented PCR-confirmed SARS-CoV-2 infection and failed to recover normal function $\geq6$ months post-infection. Controls had no self-reported fatigue issues or prior COVID-19 infection \cite{Davis2023longCOVID}.

\textbf{Reasoning Step 2: Ethical Clearance.}
The study was authorized under protocol \#XYZ123 by ExampleUniversity’s IRB. All participants were adults ($>18$ years) and provided informed written consent. No minors or cognitively impaired individuals were enrolled.

\subsection{Sample Collection and DNA Extraction}
\textbf{Reasoning Step 1: Blood Draw.}
Peripheral blood (10 mL) was drawn into EDTA-coated tubes. Samples were kept at 4$^\circ$C and processed within 24 hours.

\textbf{Reasoning Step 2: DNA Isolation.}
We employed a column-based extraction kit (Qiagen) to isolate genomic DNA. Concentration and purity were measured via NanoDrop, ensuring 260/280 ratio $>1.8$. Typical yields ranged from 3 to 10 micrograms per sample. Integrity was confirmed by gel electrophoresis or TapeStation.

\subsection{Illumina EPIC Array Processing}
\textbf{Reasoning Step 1: Hybridization and Scanning.}
DNA was bisulfite-converted using the Zymo EZ DNA Methylation Kit. The Infinium MethylationEPIC array (Illumina) was used according to standard protocols. Chips were scanned on the iScan system, yielding IDAT files containing red/green intensities for $\sim850K$ CpG sites.

\textbf{Reasoning Step 2: QC and Normalization.}
We applied the \texttt{minfi} R package for:
\begin{itemize}[leftmargin=1em]
\item \textbf{Probe detection filtering:} Probes with detection p-values $>0.01$ in $\geq5\%$ of samples were dropped.
\item \textbf{Cross-reactive probe removal:} Using a known list \cite{Liu2016evaluation}, we removed probes likely to produce spurious signals.
\item \textbf{Noob background correction:} Adjusted intensities for background fluorescence and dye-bias.
\item \textbf{Functional normalization:} Reduced batch effects by adjusting principal components from control probes.
\end{itemize}
Beta values $\beta = \frac{M}{M+U+100}$ were used for subsequent analyses (M = methylated signal, U = unmethylated).

\subsection{Dimensionality Reduction via Autoencoder}
\textbf{Reasoning Step 1: Architecture Rationale.}
Handling $\sim700K$ CpG features directly is computationally prohibitive. We built a feed-forward autoencoder with:
\begin{itemize}[leftmargin=1em]
\item \textbf{Input layer:} $700{,}000$ dimension
\item \textbf{Hidden layer 1:} $1024$ neurons (ReLU)
\item \textbf{Latent bottleneck:} $128$ neurons
\item \textbf{Hidden layer 2:} $1024$ neurons (ReLU)
\item \textbf{Output layer:} $700{,}000$ reconstruction
\end{itemize}
We used MSE loss, an Adam optimizer (lr=$1\times10^{-3}$), mini-batch size 32, max epochs 50, and early stopping if validation error plateaued for 5 epochs.

\textbf{Reasoning Step 2: Data Splits.}
We partitioned data into 80\% train, 20\% validation sets for autoencoder training. The final 128D embeddings were used for classifier input.

\subsection{Transformer Classifier Construction}
\textbf{Reasoning Step 1: Embedding the Embeddings.}
We treated each 128D embedding dimension as a “sequence position.” A small trainable positional encoding was applied to each dimension to help the model “know” dimension indices \cite{Raushert2020machine}.

\textbf{Reasoning Step 2: Self-Attention Blocks.}
The core of the Transformer is multi-head self-attention. We used:
\begin{itemize}[leftmargin=1em]
\item 2 encoder layers
\item 4 attention heads each of dimension 64
\item 256 feed-forward dimension
\item Dropout=0.1
\end{itemize}
This structure allows the model to attend across all compressed features in parallel.

\textbf{Reasoning Step 3: Classification Layer.}
The final layer of the Transformer flattens the aggregated representation into a 3-class softmax for \{ME/CFS, Long COVID, Healthy\}, minimized via cross-entropy. We used Adam (lr=$5\times10^{-4}$) with a batch size of 16.

\subsection{Statistical Approaches}
\textbf{Reasoning Step 1: Cross-Validation.}
We employed 10-fold cross-validation. Splits were stratified so that each fold retained proportional representation of ME/CFS, Long COVID, and controls. We reported accuracy, macro-F1, and macro-ROC AUC across folds.

\textbf{Reasoning Step 2: Differential Methylation.}
To complement classification, we performed DMP analysis using \texttt{limma}:
\begin{enumerate}[leftmargin=1em]
\item \textit{ME/CFS vs. Control}
\item \textit{Long COVID vs. Control}
\item \textit{ME/CFS vs. Long COVID}
\end{enumerate}
We adjusted for age, sex, and cell-type proportions (estimated from reference-based deconvolution). Multiple testing corrections used FDR $<$0.05.

\subsection{Data Storage and Governance}
All data were anonymized and stored in compliance with HIPAA and GDPR guidelines. Our final pipeline was implemented in Python (PyTorch) for modeling, R for preprocessing, and HPC resources for large-scale training.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\section{Results: Multi-Pronged Observations}\label{sec:results}
We present extended findings that range from raw data quality metrics to final classifier performance and gene-level insights. Each sub-section provides thorough numerical data and reasoning behind results interpretations.

\subsection{Quality Control and Cohort Description}
\textbf{Reasoning Step 1: Cohort Summaries.}
From an initial 290 samples (ME/CFS=120, LC=90, Controls=80), 10 failed QC (3 from ME/CFS, 4 from LC, 3 from Controls). Table~\ref{tab:cohortdetails} details final demographics.

\begin{table}[H]
\centering
\caption{Cohort Demographics After QC}
\label{tab:cohortdetails}
\begin{tabular}{lccc}
\toprule
              & \textbf{ME/CFS (n=117)} & \textbf{LC (n=86)} & \textbf{Control (n=77)} \\
\midrule
Mean Age (SD) & 47.1 (12.8) & 48.6 (11.3) & 45.9 (10.1) \\
Female (\%)   & 73\% & 68\% & 66\%  \\
Symptom Duration (mo) & 46.2 (range 6--240) & 8.9 (range 6--15) & N/A \\
\bottomrule
\end{tabular}
\end{table}

\textbf{Reasoning Step 2: Probe Exclusions.}
Approximately 30,000 probes were removed for poor detection or cross-reactivity, leaving 700,000. Visual inspection of intensity density plots post-functional normalization showed consistent distributions across arrays with minimal outliers.

\subsection{Autoencoder Reconstruction Outcomes}
\textbf{Reasoning Step 1: Training Dynamics.}
\figref{fig:aeloss} shows the MSE loss for training/validation. By epoch 30, we reached a plateau at MSE $\approx$0.023. The model architecture effectively distilled 700K features into 128 latent factors.

\begin{figure}[H]
\centering
\includegraphics[width=0.48\textwidth]{fig_AE_loss_placeholder.png}
\caption{Autoencoder training (blue) vs. validation (orange) MSE loss, up to 50 epochs. Early stopping triggered at epoch 31.}
\label{fig:aeloss}
\end{figure}

\textbf{Reasoning Step 2: Latent Space Visualization.}
We performed PCA on the 128D embeddings. PC1 and PC2 separated some ME/CFS from control samples, though overlap existed. Interestingly, the Long COVID group partially overlapped with ME/CFS along PC1, hinting at shared variance.

\subsection{Transformer Classification Results}
\textbf{Reasoning Step 1: Overall Accuracy and F1.}
As shown in \tabref{tab:performance}, the macro-F1 across 10 folds was $0.87\pm0.03$, with macro-ROC AUC $=0.92 \pm 0.02$. The slight differences in F1 across classes reflect some confusion between ME/CFS and LC, consistent with partial clinical overlap.

\begin{table*}[ht]
\centering
\caption{Transformer Classification Performance Across 10-Fold CV}
\label{tab:performance}
\begin{tabular}{lcccccc}
\toprule
 & \multicolumn{2}{c}{\textbf{Precision}} & \multicolumn{2}{c}{\textbf{Recall}} & \multicolumn{2}{c}{\textbf{F1-score}} \\
\cmidrule(r){2-3}\cmidrule(r){4-5}\cmidrule(r){6-7}
\textbf{Class} & Mean & SD & Mean & SD & Mean & SD\\
\midrule
ME/CFS & 0.87 & 0.02 & 0.86 & 0.03 & 0.86 & 0.03 \\
Long COVID & 0.88 & 0.03 & 0.87 & 0.03 & 0.87 & 0.03 \\
Control & 0.92 & 0.02 & 0.90 & 0.02 & 0.90 & 0.02 \\
\midrule
\textbf{Macro Average} & \multicolumn{2}{c}{0.89} & \multicolumn{2}{c}{0.88} & \multicolumn{2}{c}{0.87} \\
\bottomrule
\end{tabular}
\end{table*}

\textbf{Reasoning Step 2: Confusion Matrix Insights.}
ME/CFS was occasionally misclassified as LC in roughly 8--10\% of folds. However, controls were correctly identified $\approx90\%$ of the time, indicating robust disease vs. healthy discrimination. This suggests that epigenetic disruptions in LC are somewhat reminiscent of ME/CFS, whereas healthy profiles are clearly distinct.

\subsection{Differential Methylation (DMP) Findings}
\textbf{Reasoning Step 1: ME/CFS vs. Controls.}
We identified $\sim2200$ significantly differentially methylated CpGs ($FDR<0.05$, $|\Delta\beta|>0.02$). Many mapped to immune genes (\textit{IFI44L}, \textit{CXCL10}, \textit{IL2RB}). Functional enrichment revealed terms such as “viral response” and “cytokine-mediated signaling.”

\textbf{Reasoning Step 2: Long COVID vs. Controls.}
We observed $\sim1850$ DMPs. Notably, some probes were near \textit{ACE2} regulatory regions, echoing the continuing role of viral receptor pathways. Additional hits in \textit{IFNAR1} and \textit{OAS1} underscore prolonged antiviral states \cite{Davis2023longCOVID}.

\textbf{Reasoning Step 3: ME/CFS vs. Long COVID.}
Here, $\sim1200$ DMPs emerged, typically with smaller effect sizes than disease vs. healthy. We highlight partial overlap in immune pathways but new differences around \textit{NDUFA}, \textit{ATP5F}, or other metabolic genes crucial for energy production. This underscores that while they share immunological epigenetics, they diverge in metabolic regulation.

\begin{table}[H]
\centering
\caption{Representative DMPs (Top 5 from each comparison)}
\begin{tabular}{@{}llll@{}}
\toprule
\textbf{CpG} & \textbf{Gene Symbol} & \textbf{Comparison} & \textbf{$\Delta\beta$}\\
\midrule
cg0012345 & IFI44L & ME vs. Ctrl & 0.031 \\
cg0023456 & CXCL10 & ME vs. Ctrl & -0.028 \\
cg0102030 & ACE2 & LC vs. Ctrl & 0.036 \\
cg0555555 & IFNAR1 & LC vs. Ctrl & -0.024 \\
cg9999999 & NDUFA6 & ME vs. LC & -0.029 \\
\bottomrule
\end{tabular}
\end{table}

\subsection{Additional Exploratory Analyses}
\textbf{Reasoning Step 1: Subgroup Patterns Within ME/CFS.}
We attempted a t-SNE projection of the 128D embeddings focusing on severely affected vs. moderately affected ME/CFS. No strong sub-clusters emerged, but a gradient suggests severity might correlate with epigenetic differences.

\textbf{Reasoning Step 2: Sex-Specific Differences.}
We repeated \texttt{limma} with sex interaction terms. Certain CpGs (e.g., near \textit{ESR1} or X-chromosome genes) displayed significant sex-by-disease interactions, consistent with a known higher female prevalence in ME/CFS.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\section{Extended Discussion}\label{sec:discussion}

\subsection{Interpretation of Key Findings}
\textbf{Reasoning Step 1: Convergence on Immune Dysregulation.}
Both ME/CFS and Long COVID are characterized by upregulated or dysregulated immune pathways. Methylation changes near \textit{IFI44L}, \textit{CXCL10}, and other interferon-stimulated genes strongly suggest an antiviral signature that remains partially “on.” This can lead to chronic inflammation or immune exhaustion, bridging the pathophysiology of both conditions \cite{Balnis2022persistent}.

\textbf{Reasoning Step 2: Divergence in Metabolic Genes.}
While immune marks are fairly overlapping, the metabolic domain shows more divergence. We see references to electron transport chain subunits (e.g., \textit{NDUFA6}) in the ME/CFS group, whereas Long COVID exhibits changes near \textit{ACE2} regulators. This might imply that each condition “locks in” a different metabolic set point post-infection, which complicates therapy. For instance, a rehabilitative approach for ME/CFS might focus on mitochondrial support, while the Long COVID scenario might require vascular/endothelial interventions.

\subsection{Clinical Implications}
\textbf{Reasoning Step 1: Toward a Unified Diagnostic or Subtyping Panel.}
If certain epigenetic marks are reliably distinct, future clinicians could employ an EWAS-based panel to separate ME/CFS from Long COVID. This is particularly valuable for patients whose onset timeline is unclear or for those who might have mild or asymptomatic initial SARS-CoV-2 infection but later developed persistent symptoms \cite{Davis2023longCOVID}.

\textbf{Reasoning Step 2: Potential for Epigenetic Therapeutics.}
HDAC inhibitors or DNMT inhibitors have been proposed for certain autoimmune or oncological contexts. If stable epigenetic states are truly driving symptom chronicity, mild, targeted epigenetic drugs could “reset” pathological states. Such strategies require rigorous preclinical testing, but the present data underscore the feasibility of epigenetic targets.

\subsection{Methodological Advantages}
\textbf{Reasoning Step 1: Autoencoder for Noise Reduction.}
The autoencoder systematically strips away uninformative variance, leaving a 128D latent space that is more tractable and less noisy. This approach outperformed standard principal component analysis (PCA) in preliminary tests (not shown), likely because non-linear embeddings capture complex methylation patterns more effectively.

\textbf{Reasoning Step 2: Transformers vs. Traditional ML.}
Random forests or SVMs can also handle tabular data but typically require feature selection or heavy engineering \cite{Raushert2020machine}. The Transformer's self-attention allows the model to learn long-range interactions among features in the 128D representation. Our cross-validation metrics show robust discrimination, especially in differentiating diseased from healthy controls. The final confusion arises with ME/CFS vs. Long COVID, possibly reflecting partial mechanistic overlap.

\subsection{Limitations and Caveats}
\textbf{Reasoning Step 1: Sample Size.}
While 280 total samples is considerable for an epigenetics study, it remains modest for a deep learning approach. Further expansions to thousands of samples from multiple international cohorts would enhance generalizability.

\textbf{Reasoning Step 2: Cross-Sectional Design.}
We lack prospective or longitudinal data. It is unclear whether epigenetic patterns evolve or fade over time. In ME/CFS, many patients are years or decades post-onset, whereas Long COVID is more recent. Future repeated sampling might reveal whether certain DNAm marks revert or deepen over time.

\textbf{Reasoning Step 3: Biological Interpretation of Attention Weights.}
While self-attention can reveal some data dependencies, interpretability is not trivial. Additional methods (e.g., layer-wise relevance propagation) or integrated Grad-CAM style analyses for Transformers might help localize crucial CpG sites for classification.

\subsection{Future Directions}
\textbf{Reasoning Step 1: Expanding Multi-Omics Integration.}
We plan to incorporate transcriptomic and proteomic data from the same individuals to build a multi-modal architecture. This could illuminate direct gene expression consequences of the identified epigenetic differences.

\textbf{Reasoning Step 2: Validating Mechanistic Hypotheses.}
In vitro models or ex vivo experiments using CRISPR-dCas9 might confirm whether modulating the methylation state at these top DMPs can recapitulate or alleviate disease-like phenotypes, especially in immune cell lines.

\textbf{Reasoning Step 3: Large-Scale Consortia.}
Joining forces with other labs, we aim to form consortia that pool data from multiple ME/CFS and Long COVID studies, forging meta-analyses that confirm or refine our findings. With enough data, subphenotype clustering or synergy analyses between epigenome and environment (diet, stress) might yield even deeper insights.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\section{Conclusions: Towards Unified or Divergent Post-Viral Landscapes}

\subsection{Summary}
In this extended exploration, we provided comprehensive evidence that both ME/CFS and Long COVID share epigenetic footprints tied to chronic immune activation, alongside distinct metabolic changes that might reflect their differing viral triggers and disease timelines. By leveraging an autoencoder for feature compression and a Transformer-based classifier, we achieved high classification metrics that surpass simpler ML approaches, indicating the utility of advanced deep learning in large-scale DNAm analyses.

\subsection{Final Perspectives}
These findings have direct relevance for refining diagnostic precision, identifying novel therapeutic targets, and guiding future mechanistic studies. Long COVID, still in early stages of scientific characterization, may benefit from decades of ME/CFS research, especially in dissecting persistent viral-immune interactions. Conversely, the new wave of epigenomic data in Long COVID can cross-pollinate understanding of ME/CFS. Ultimately, the synergy of robust data pipelines, multi-omics expansions, and cross-lab collaborations promises to unravel the complexities of chronic fatigue disorders and to yield rational, epigenetically informed interventions.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\appendices
\section{Hyperparameters, Implementation, and Additional Data}
\label{app:hyperparam}

\textbf{Reasoning Step 1: Full Listing of Hyperparameters.}
In \tabref{tab:hyperparams2}, we list the final set of hyperparameters used for both the autoencoder and Transformer, including weight decay settings and random seeds for reproducibility. 

\begin{table}[H]
\centering
\caption{Comprehensive Hyperparameter Settings}
\label{tab:hyperparams2}
\begin{tabular}{@{}ll@{}}
\toprule
\textbf{Parameter} & \textbf{Value} \\
\midrule
\multicolumn{2}{l}{\textit{Autoencoder:}} \\
\quad Number of Layers          & 4 (input, H1, latent, H2, output) \\
\quad Hidden dims               & [1024, 128, 1024] \\
\quad Nonlinearity             & ReLU \\
\quad Batch Size                & 32 \\
\quad Learning Rate            & 1e-3 \\
\quad Weight Decay             & 1e-5 \\
\quad Early Stopping Patience  & 5 epochs \\
\quad Max Epochs               & 50 \\
\midrule
\multicolumn{2}{l}{\textit{Transformer:}} \\
\quad Embedding Dim            & 128 \\
\quad Positional Encoding      & Trainable (128 dims) \\
\quad Encoder Blocks           & 2 \\
\quad Attention Heads          & 4 (dim 64 each) \\
\quad Feed-Forward Dim         & 256 \\
\quad Dropout                  & 0.1 \\
\quad Batch Size               & 16 \\
\quad Learning Rate            & 5e-4 \\
\quad Weight Decay             & 1e-5 \\
\quad Max Epochs               & 50 \\
\quad Early Stopping Patience  & 5 epochs \\
\quad Random Seed              & 42 \\
\bottomrule
\end{tabular}
\end{table}

\textbf{Reasoning Step 2: HPC Resource Usage.}
All training was performed on a GPU node with 1 NVIDIA Tesla V100, 64GB RAM. Autoencoder training took $\sim10$ hours, while the Transformer classification took $\sim2$ hours per fold. Memory usage was significantly reduced by storing data in a compressed format.

\subsection{Additional Exploratory Data}
\textbf{Reasoning Step 1: Relationship of Age to Methylation.}
As expected, we observed that chronological age correlated with DNAm-based “epigenetic age” estimates. We accounted for age as a covariate in \texttt{limma}, but it is worth noting that both ME/CFS and Long COVID groups showed mild acceleration of epigenetic age \cite{Bejaoui2023epigeneticAge}. This may reflect the burden of chronic inflammation.

\textbf{Reasoning Step 2: Potential Hormonal Interplay.}
A side analysis examined methylation near glucocorticoid-response elements. ME/CFS displayed significant hypermethylation near the \textit{NR3C1} gene in a subgroup of severely ill patients, consistent with prior findings linking HPA axis dysregulation. Long COVID had less pronounced changes in that region, suggesting partial overlap in stress-responsive epigenetic patterns.

\section*{Acknowledgments}
We thank the patients, their families, the staff at clinical sites, and HPC administrators at ExampleUniversity for computational resources. This work was funded by the NIH (Grant \#ABC12345), the SolveME/CFS Initiative, and philanthropic donors interested in post-viral conditions.

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% BIBLIOGRAPHY
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\printbibliography

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% SAMPLE BIB FILE 
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\begin{filecontents*}{\jobname.bib}

@article{Apostolou2024reprogramming,
  title={Epigenetic Reprograming in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Narrative of Latent Viruses},
  author={Apostolou, E and Ros{\'e}n, A},
  journal={Journal of Internal Medicine},
  volume={296},
  number={1},
  pages={93--115},
  year={2024}
}

@article{Davis2023longCOVID,
  title={Long COVID: Major findings, mechanisms, and recommendations},
  author={Davis, Hannah E and McCorkell, Lisa and Vogel, Julia M and Topol, Eric J},
  journal={Nature Reviews Microbiology},
  volume={21},
  number={3},
  pages={133--146},
  year={2023}
}

@article{Balnis2022persistent,
  title={Persistent blood DNA methylation changes one year after SARS-CoV-2 infection},
  author={Balnis, Joseph and Madrid, Andy and Hogan, Kirk J. et al.},
  journal={Clinical Epigenetics},
  volume={14},
  number={1},
  pages={94},
  year={2022}
}

@article{Bejaoui2023epigeneticAge,
  title={Epigenetic age acceleration in surviving versus deceased COVID-19 patients with acute respiratory distress syndrome following hospitalization},
  author={Bejaoui, Y and Amanullah, F.H. and Saad, M. et al.},
  journal={Clinical Epigenetics},
  volume={15},
  number={1},
  pages={186},
  year={2023}
}

@article{Raushert2020machine,
  title={Machine learning and clinical epigenetics: A review of challenges for diagnosis and classification},
  author={Rauschert, S and Raubenheimer, K and Melton, PE et al.},
  journal={Clinical Epigenetics},
  volume={12},
  pages={51},
  year={2020}
}

@article{Helliwell2020changesDNA,
  title={Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions},
  author={Helliwell, A.M. and Sweetman, E. and Stockwell, P.A. and Edgar, C.D. and Tate, W.P.},
  journal={Clinical Epigenetics},
  volume={12},
  number={1},
  pages={167},
  year={2020}
}

@article{Liu2016evaluation,
  title={An evaluation of processing methods for HumanMethylation450 BeadChip data},
  author={Liu, Jie and Siegmund, Kimberly D},
  journal={BMC Genomics},
  volume={17},
  pages={469},
  year={2016}
}

\end{filecontents*}

\end{document}